Healthcare Industry News: drug-eluting stent
News Release - October 19, 2006
Medtronic Announces Key Activities at Transcatheter Cardiovascular Therapeutics (TCT) Meeting
Company to Present New Clinical Data from The Endeavor drug-eluting stent ProgramMINNEAPOLIS--(HSMN NewsFeed)--Medtronic (NYSE:MDT ) today announced its key activities at next week's 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. Among the highlights are:
- New stent thrombosis data on the Endeavor® zotarolimus-eluting coronary stent system following a retrospective review by an independent physician panel
- Presentation of early results from the Endeavor RESOLUTE clinical trial by Prof. Ian Meredith, Monash Medical Centre, Melbourne, Australia
- An analyst briefing hosted by Medtronic Investor Relations that will focus on the latest clinical and market developments in the Endeavor stent program
"TCT provides an excellent scientific forum to add to the extensive body of clinical and market data on the Endeavor drug-eluting stent," said Scott Ward, president of the Vascular business at Medtronic. "The issue of drug-eluting stent safety will be a central theme at this year's TCT, and we will be providing further clinical evidence of the Endeavor stent's strong safety profile - particularly as it relates to stent thrombosis. We look forward to highlighting the improvements that a new class of drug-eluting stents can bring to physicians and patients."
Here is Medtronic's schedule of major events at TCT (all times U.S. Eastern Daylight Time):
Monday, Oct. 23
Physician Symposium: 7-10 p.m. ET; Grand Hyatt Hotel, Independence Ballroom. "Drug Eluting Stents: State of the Nation." Moderated by Dr. Martin Leon, Columbia University Medical Center, this evening physician symposium will offer a comprehensive look at the drug-eluting stent landscape. Speakers include: Dr. Peter Fitzgerald, Stanford School of Medicine, Palo Alto, CA; Dr. Jean Marco, Clinique Pasteur, Toulouse, France; Dr. William Wijns, Co-Director of the Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium; and Dr. Alan Yeung, Stanford School of Medicine, Palo Alto, CA.
Tuesday, Oct. 24
Investor Relations Analyst Meeting/Webcast: 2:30-4:00 p.m. ET; Embassy Suites, Convention Center Hotel, Capital B/C ballroom. Medtronic management will provide a review of the vascular business, with a focus on the Endeavor drug-eluting stent program. The meeting will be webcast through the Investor Relations link on the company website at www.medtronic.com.
Wednesday, Oct. 25
"First Report Investigation" Session: 1:30 p.m. ET; Washington Convention Center, Main Arena. "RESOLUTE - First-in-Man Registry with Endeavor RESOLUTE Zotarolimus-Eluting Stents: Four-Month Clinical, Angiographic, and Intravascular Ultrasound Results." Prof. Ian Meredith, Monash Medical Centre, Melbourne, Australia, will present early results from the RESOLUTE trial. Endeavor RESOLUTE is Medtronic's next drug-eluting stent innovation, incorporating a proprietary, highly biocompatible polymer. The RESOLUTE DES system is designed specifically to treat the most challenging clinical conditions. Medtronic will issue a news release following this presentation.
Medtronic will occupy booth #628 at the Washington Convention Center. Among the many activities in the booth will be daily patient simulator demonstrations of the Medtronic MX2, a unique short-wire delivery system for coronary stents and balloons. This proprietary delivery system offers the option for wire exchanges, plus the speed and ease of operation of short-wire systems.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
Caution: In the United States, the Endeavor and Endeavor RESOLUTE Drug-Eluting Coronary Stents are investigational devices with an investigational drug (zotarolimus) and used exclusively for clinical investigation.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results.
Source: Medtronic
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Medtronic appoints Thierry Piéton as Chief Financial OfficerMedtronic Achieves CE Mark Approval for BrainSense Adaptive Deep Brain Stimulation and Electrode Identifier, a Groundbreaking Advance In Personalized, Sensing-Enabled Care for People with Parkinson's Through Innovative Brain-Computer Interface Technology
Medtronic Receives FDA Clearance for New InPen(TM) App, Paving the Way for its Smart MDI System Launch with Simplera(TM) CGM
